The Next Great Blockbuster Biotech Stock to Buy Now

Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.

biotech stockThat's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.

Take Puma Biotechnology Inc. (NYSE: PBYI), for example. The company released positive clinical trial results on a breast cancer drug in July 2014, and its stock soared 300% in one trading session.

CytRX Corp. (NASDAQ: CYTR) announced positive results from its brain cancer drug on Jan. 7, 2015, and its stock climbed almost 16% in one day. Year to date, it's up 46%.

Now, Money Morning Biotech Investing Specialist Ernie Tremblay has found a new biotech stock to buy that could be the next cancer blockbuster...

Finding the Next Blockbuster Biotech Stocks

Picking the next biotech stock winner is difficult. When it comes to finding successful cancer treatment drugs, Tremblay says "the odds are not in your favor."

That's because fewer than 10% of experimental drugs designed to treat solid tumors make it to final Food and Drug Administration approval, according to a study by Clinical Pharmacology and Therapeutics. So if you picked 10 biotech stocks, you'd be lucky to find one successful drug.

Drugs designed to treat blood cancers have a higher success rate, but it's still low at just 36%.

But now one company is working on a new type of cancer treatment, and it could create the next blockbuster biotech stock.

You see, when cells get sick or damaged, the body sends scavenger cells called macrophages to devour them. This process is called phagocytosis.

"Nearby healthy cells avoid this fate because they carry significant amounts of a signal protein, CD47, on their surfaces, which acts like a flashing sign that says, 'Do not eat me!'" Tremblay explained. "Unhealthy cells lose much of their ability to express CD47 and also give off other signals that attract hungry macrophages. They quickly become lunch."

Unfortunately, cancer cells have the ability to produce CD47 and camouflage themselves.

That has scientists working to develop a CD47 blockade. It's a treatment that would prevent cancer cells from producing the protein.

"This approach to fighting blood cancers is extremely promising, but it's not the end of the story," Tremblay said. "As it turns out, CD47 blockade may be a treatment that works against all cancers - there are more than 200 variations - because all malignant tumors, no matter the type, express CD47 for survival.

"Until now, researchers have assumed there would never be this kind of 'magic bullet.'"

And one company in particular is at the forefront of this new treatment...

One Revolutionary Biotech Stock to Buy Today

The biotech stock Tremblay recommends is Trillium Therapeutics Inc. (Nasdaq: TRIL).

Trillium is working on a CD47 inhibitor called SIRPαFc. It binds a protein to the CD47, preventing it from broadcasting the "don't eat me" signal.

[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]

One of the biggest questions with CD47 inhibitors is whether they will also attack healthy red blood cells. Fortunately, that's not the case with SIRPαFc. The drug binds well with cancer cells, but not with blood cells.

The company is set to begin phase 1 trials for treatment of acute myeloid leukemia (AML).

"Trillium is a remarkable investment opportunity," Tremblay said. "For AML alone, assuming an annual treatment cost of around $75,000 per year, averaged worldwide, and a peak market penetration of 23%, sales could top $900 million for this indication alone."

And this biotech stock won't limit its focus to just AML. Trillium is researching blood cancers and solid tumors as well.

"If CD47 blockade works as well as the science predicts it should, TRIL's earning potential will be unlimited," Tremblay said.

TRIL is a speculative biotech stock play, with a market cap of just $162 million. But the company's potential is undeniable. Year to date, it has already climbed 150%.

This biotech stock will likely be volatile in the short term. Tremblay typically recommends a trailing stock of 35% on biotech stocks. Shares of TRIL opened today at $23.

The Bottom Line: Cancer spending has topped $100 billion globally, but finding the best biotech stocks to buy is still challenging. Tremblay is targeting a new type of treatment known as CD47 blockades that could be the key to curing all cancers. The top play in that market now is Trillium Therapeutics. It's a biotech stock with an amazing product and huge profit potential.

Watch the video below for five easy steps to picking the best biotech stocks to buy. Improve your returns and reduce your risk today:

Follow me on Twitter @KyleAndersonMM.

Editor's Note: They call it the "Boomer Virus," and it kills every 58 seconds. A highly contagious virus is sweeping the globe and has made its way to the United States. It's 1,000 times more deadly than Ebola and kills every 58 seconds. Millions of Americans are already infected and don't even know it... and Boomers are five times more likely to contract this infection. Fortunately, a tiny $7 company is providing a patented medical breakthrough that could save 75 million Americans from a grisly death. Do not ignore this warning. It's a matter of life and death. Continue reading here...